NEULAND LABORATORIES
Back to Balance Sheet
|
NEULAND LABORATORIES Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹13 Cr | ₹8.97 Cr | ₹28 Cr | ₹91 Cr | ₹75 Cr |
What is the latest Contingent Liabilities ratio of NEULAND LABORATORIES ?
| Year | Contingent Liabilities |
|---|---|
| Mar2026 | ₹13 Cr |
| Mar2025 | ₹8.97 Cr |
| Mar2024 | ₹28 Cr |
| Mar2023 | ₹91 Cr |
| Mar2022 | ₹75 Cr |
How is Contingent Liabilities of NEULAND LABORATORIES Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹13 Cr | 46.92 | |
| Mar2025 | ₹8.97 Cr | -67.65 | |
| Mar2024 | ₹28 Cr | -69.60 | |
| Mar2023 | ₹91 Cr | 22.14 | |
| Mar2022 | ₹75 Cr | - | |
Compare Contingent Liabilities of peers of NEULAND LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NEULAND LABORATORIES | ₹28,829.2 Cr | -6.1% | -3.4% | 63.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹440,278.0 Cr | -2.5% | -4.7% | 15.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹243,966.0 Cr | -4% | 8.1% | 55.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹184,478.0 Cr | -2.3% | 0.2% | 36.6% | Stock Analytics | |
| CIPLA | ₹109,950.0 Cr | -1.7% | -6.1% | -12% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹95,967.4 Cr | -0.2% | -4.4% | -10.2% | Stock Analytics | |
NEULAND LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NEULAND LABORATORIES | -6.1% |
-3.4% |
63.3% |
| SENSEX | -2.8% |
-5.2% |
-8.4% |
You may also like the below Video Courses